Live Breaking News & Updates on ஐரோப்பிய பலதரப்பட்ட காங்கிரஸ் ஆன் சிறுநீரக புற்றுநோய்கள்

Stay updated with breaking news from ஐரோப்பிய பலதரப்பட்ட காங்கிரஸ் ஆன் சிறுநீரக புற்றுநோய்கள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

JAVELIN Bladder 100 Trial - Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma


JAVELIN Bladder 100 Trial
Interviews with Experts at Conferences
Curated by Clinicians: Educational Forum with Videos, Abstracts and Conference Information
Videos
April 23, 2021
November 17, 2020
November 16, 2020
October 14, 2020
Conference Coverage
Conference Highlights from Recent Conference Coverage
Petros Grivas, MD, PhD
In Best of Podium presentation at this year’s Southeast Section of the American Urologic Association Virtual Annual Meeting, Dr. Grivas presented pre-specified subgroup analyses of the JAVELIN Bladder 100 trial. Read More
Yohann Loriot, MD, PhD
Avelumab first-line maintenance therapy is approved in the United States for patients with advanced urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy based on significantly prolonged overall survival versus best supportive care alone (median 21.4 months versus 14.3 months; HR 0.69, 95% CI 0.56-0.86) as reporte ....

United States , Elizabeth Plimack , Petros Grivas , Shaheen Alanee , Juergen Gschwend , Matthew Galsky , Thomasb Powles , Norihiko Tsuchiya , Srikala Sridhar , Robert Dreicer , Yohann Loriot , Thomas Powles , European Society Of Medical Oncology , European Multidisciplinary Congress On Urological Cancers , Society Of Urologic Oncology , Virtual Congress , Southeast Section , Neal Shore , Urologic Oncology , Annual Virtual Meeting , Bladder Cancer , European Multidisciplinary Congress , Urological Cancers , European Society , Medical Oncology , Kilian Gust ,

Testicular, Penile, and Rare GU Malignancies


Testicular, Penile, and Rare GU Malignancies
Interviews with Experts at Conferences
Curated by clinicians: educational forums with videos, abstracts and conference information
Videos
April 27, 2021
The State-of-the-Evidence in Brief Reviews by Experts
May 17, 2021
Penile cancer (PC) is  a rare malignancy with an incidence estimated less than 1/100 000 per year in the Western World
1-3
Historically, demolitive surgical approaches, such as total or partial penile amputation, were the most commonly used. Indeed, demolitive options were deemed to be necessary in order to respect a macroscopic surgical margin of at least 2 cm.
3-4 If the oncological outcomes of these approaches demonstrated to be satisfactory, they significantly affected aesthetic outcomes, as well as sexual and urinary functions. ....

United States , New Zealand , Julien Van Damme , Pilar Laguna , Christopher Jd Wallis , Fallen James , Zachary Klaassen , Philippe Spiess , Darren Feldman , Andrea Necchi , Lucia Nappi , Philippee Spiess , Lyndal Moore , James Lynam , Silke Gillessen , Peter Albers , Alok Tewari , Andreas Hiester , Patricia Bastick , European Association Of Urology , European Multidisciplinary Congress On Urological Cancers , Moffitt Cancer Center , Global Society Of Rare Genitourinary Tumors , Cancer Trials Group , International Germ Cell Cancer Collaborative Group , Virtual Annual Congress ,

EMUC 2020: Neoadjuvant Versus Adjuvant Strategies in Locally Advanced Bladder Cancer


EMUC 2020: Neoadjuvant Versus Adjuvant Strategies in Locally Advanced Bladder Cancer
(UroToday.com) In an oral presentation in a session examining neoadjuvant versus adjuvant strategies in locally advanced bladder cancer at the 12th European Multidisciplinary Congress on Urological Cancers (EMUC), Dr. Andrea Necchi led a discussion of neoadjuvant strategies in advanced bladder cancer.
He began highlighting muscle invasive bladder cancer (MIBC) as a model for clinical research based on high rates of relapse and mortality following surgical intervention alone, the relatively poor use of neoadjuvant chemotherapy in spite of international guidelines, the poor prognosis of patients with residual MIBC following neoadjuvant chemotherapy, and the uncertainty of treatment approaches in patients who are ineligible for cisplatin. ....

Christopher Jd Wallis , Neoadjuvant Pembrolizumab , Andrea Necchi , European Multidisciplinary Congress On Urological Cancers , Vanderbilt University Medical Center , European Multidisciplinary Congress , Urological Cancers , Muscle Invasive Urothelial Bladder Carcinoma , Neo Adjuvant Bladder Urothelial Carcinoma , Medical Oncologist , Italy Written , Urologic Oncology Fellow , கிறிஸ்டோபர் ஜ்ட் வாலிஸ் , ஆண்ட்ரியா னேக்சி , ஐரோப்பிய பலதரப்பட்ட காங்கிரஸ் ஆன் சிறுநீரக புற்றுநோய்கள் , வாண்டர்பில்ட் பல்கலைக்கழகம் மருத்துவ மையம் , ஐரோப்பிய பலதரப்பட்ட காங்கிரஸ் , சிறுநீரக புற்றுநோய்கள் , மருத்துவ புற்றுநோயியல் நிபுணர் , இத்தாலி எழுதப்பட்டது , சிறுநீரக புற்றுநோயியல் சக ,